Decline in ADT Not at Expense of Men With Prostate Cancer

Decline in ADT Not at Expense of Men With Prostate Cancer

Medicare paid out about $1 billion for gonadotropin-releasing hormone (GnRH) agonists used in the treatment of prostate cancer. By 2005, the payout for these drugs, known as androgen-deprivation therapy (ADT), was reduced to about $400 million.